根据ESI于2025年5月发布的数据，我校高被引论文（Highly Cited Papers）564篇，热点论文（Hot Papers）26篇，见附件：2025年5月南方医科大学高被引论文及热点论文简表。详情如下。
从学科角度看，在564篇高被引论文中，临床医学最多（276篇），占比48.94%，药理学与毒理学49篇（8.69%）紧跟其后。
|
序号 |
高被引论文 Research Field |
2025.5 |
2025.3 |
||
|
论文数 |
占比 |
论文数 |
占比 |
||
|
１ |
CLINICAL MEDICINE |
276 |
48.94% |
272 |
47.55% |
|
2 |
MOLECULAR BIOLOGY & GENETICS |
41 |
7.27% |
42 |
7.34% |
|
3 |
BIOLOGY & BIOCHEMISTRY |
37 |
6.56% |
39 |
6.82% |
|
4 |
PHARMACOLOGY & TOXICOLOGY |
49 |
8.69% |
48 |
8.39% |
|
5 |
MATERIALS SCIENCE |
40 |
7.09% |
40 |
6.99% |
|
6 |
NEUROSCIENCE & BEHAVIOR |
15 |
2.66% |
19 |
3.32% |
|
7 |
ENGINEERING |
10 |
1.77% |
11 |
1.92% |
|
8 |
MICROBIOLOGY |
14 |
2.48% |
14 |
2.45% |
|
9 |
CHEMISTRY |
9 |
1.60% |
9 |
1.57% |
|
10 |
PHYSICS |
17 |
3.01% |
18 |
3.15% |
|
11 |
PSYCHIATRY/PSYCHOLOGY |
13 |
2.30% |
15 |
2.62% |
|
12 |
IMMUNOLOGY |
12 |
2.13% |
13 |
2.27% |
|
13 |
SOCIAL SCIENCES, GENERAL |
9 |
1.60% |
9 |
1.57% |
|
14 |
COMPUTER SCIENCE |
7 |
1.24% |
8 |
1.40% |
|
15 |
AGRICULTURAL SCIENCES |
6 |
1.06% |
6 |
1.05% |
|
16 |
MULTIDISCIPLINARY |
1 |
0.18% |
1 |
0.17% |
|
17 |
ENVIRONMENT/ECOLOGY |
7 |
1.24% |
7 |
1.22% |
|
18 |
MATHEMATICS |
1 |
0.18% |
1 |
0.17% |
|
|
合计 |
564 |
100.00% |
572 |
100.00% |
|
序号 |
2025年5月我校26篇热点论文 标题 |
来源期刊 |
DOI |
Research Field |
Times Cited |
|
1 |
MINIMAL INFORMATION FOR STUDIES OF EXTRACELLULAR VESICLES (MISEV2023): FROM BASIC TO ADVANCED APPROACHES |
JOURNAL OF EXTRACELLULAR VESICLES 13 (2): - FEB 2024 |
10.1002/jev2.12404 |
BIOLOGY & BIOCHEMISTRY |
774 |
|
2 |
GLOBAL INCIDENCE, PREVALENCE, YEARS LIVED WITH DISABILITY (YLDS), DISABILITY-ADJUSTED LIFE-YEARS (DALYS), AND HEALTHY LIFE EXPECTANCY (HALE) FOR 371 DISEASES AND INJURIES IN 204 COUNTRIES AND TERRITORIES AND 811 SUBNATIONAL LOCATIONS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2133-2161 MAY 18 2024 |
10.1016/S0140-6736(24)00757-8 |
CLINICAL MEDICINE |
413 |
|
3 |
GLOBAL BURDEN OF 288 CAUSES OF DEATH AND LIFE EXPECTANCY DECOMPOSITION IN 204 COUNTRIES AND TERRITORIES AND 811 SUBNATIONAL LOCATIONS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2100-2132 MAY 18 2024 |
10.1016/S0140-6736(24)00367-2 |
CLINICAL MEDICINE |
349 |
|
4 |
GLOBAL BURDEN AND STRENGTH OF EVIDENCE FOR 88 RISK FACTORS IN 204 COUNTRIES AND 811 SUBNATIONAL LOCATIONS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2162-2203 MAY 18 2024 |
10.1016/S0140-6736(24)00933-4 |
CLINICAL MEDICINE |
317 |
|
5 |
CAMRELIZUMAB PLUS RIVOCERANIB VERSUS SORAFENIB AS FIRST-LINE THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (CARES-310): A RANDOMISED, OPEN-LABEL, INTERNATIONAL PHASE 3 STUDY |
LANCET 402 (10408): 1133-1146 SEP 30 2023 |
10.1016/S0140-6736(23)00961-3 |
CLINICAL MEDICINE |
260 |
|
6 |
ESTIMATED BURDEN OF STROKE IN CHINA IN 2020 |
JAMA NETWORK OPEN 6 (3): - MAR 2023 |
10.1001/jamanetworkopen.2023.1455 |
CLINICAL MEDICINE |
250 |
|
7 |
OVERALL SURVIVAL WITH OSIMERTINIB IN RESECTED <I>EGFR</I>-MUTATED NSCLC |
NEW ENGLAND JOURNAL OF MEDICINE 389 (2): 137-147 JUL 13 2023 |
10.1056/NEJMoa2304594 |
CLINICAL MEDICINE |
223 |
|
8 |
GLOBAL AGE-SEX-SPECIFIC MORTALITY, LIFE EXPECTANCY, AND POPULATION ESTIMATES IN 204 COUNTRIES AND TERRITORIES AND 811 SUBNATIONAL LOCATIONS, 1950-2021, AND THE IMPACT OF THE COVID-19 PANDEMIC: A COMPREHENSIVE DEMOGRAPHIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 1989-2056 MAY 18 2024 |
10.1016/S0140-6736(24)00476-8 |
CLINICAL MEDICINE |
210 |
|
9 |
BURDEN OF DISEASE SCENARIOS FOR 204 COUNTRIES AND TERRITORIES, 2022-2050: A FORECASTING ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2204-2256 MAY 18 2024 |
10.1016/S0140-6736(24)00685-8 |
CLINICAL MEDICINE |
154 |
|
10 |
GUIDELINES FOR THE PREVENTION AND TREATMENT OF CHRONIC HEPATITIS B (VERSION 2022) |
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY 11 (6): 1425-1442 NOV 2023 |
10.14218/JCTH.2023.00320 |
CLINICAL MEDICINE |
145 |
|
11 |
AGGREGATION-INDUCED EMISSION (AIE), LIFE AND HEALTH |
ACS NANO 17 (15): 14347-14405 JUL 24 2023 |
10.1021/acsnano.3c03925 |
MATERIALS SCIENCE |
136 |
|
12 |
ALECTINIB IN RESECTED <I>ALK</I>-POSITIVE NON-SMALL-CELL LUNG CANCER |
NEW ENGLAND JOURNAL OF MEDICINE 390 (14): 1265-1276 APR 11 2024 |
10.1056/NEJMoa2310532 |
CLINICAL MEDICINE |
89 |
|
13 |
PHOTOTHERMAL THERAPY OF TUBERCULOSIS USING TARGETING PRE-ACTIVATED MACROPHAGE MEMBRANE-COATED NANOPARTICLES |
NATURE NANOTECHNOLOGY 19 (6): - JUN 2024 |
10.1038/s41565-024-01618-0 |
MATERIALS SCIENCE |
75 |
|
14 |
GLOBAL FERTILITY IN 204 COUNTRIES AND TERRITORIES, 1950-2021, WITH FORECASTS TO 2100: A COMPREHENSIVE DEMOGRAPHIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2057-2099 MAY 18 2024 |
10.1016/S0140-6736(24)00550-6 |
CLINICAL MEDICINE |
73 |
|
15 |
EVALUATION AND TREATMENT OF KNEE PAIN A REVIEW |
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 330 (16): 1568-1580 OCT 24 2023 |
10.1001/jama.2023.19675 |
CLINICAL MEDICINE |
71 |
|
16 |
TORIPALIMAB PLUS CHEMOTHERAPY FOR RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA THE JUPITER-02 RANDOMIZED CLINICAL TRIAL |
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 330 (20): 1961-1970 NOV 28 2023 |
10.1001/jama.2023.20181 |
CLINICAL MEDICINE |
66 |
|
17 |
THE CHINESE SOCIETY OF CLINICAL ONCOLOGY (CSCO): CLINICAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF GASTRIC CANCER, 2023 |
CANCER COMMUNICATIONS : - DEC 31 2023 |
10.1002/cac2.12516 |
CLINICAL MEDICINE |
66 |
|
18 |
PULMONARY HYPERTENSION |
NATURE REVIEWS DISEASE PRIMERS 10 (1): - JAN 4 2024 |
10.1038/s41572-023-00486-7 |
CLINICAL MEDICINE |
62 |
|
19 |
DETECTION AND ANALYSIS OF SIGNALS OF ADVERSE EVENTS OF MEMANTINE BASED ON THE US FOOD AND DRUG ADMINISTRATION ADVERSE EVENT REPORTING SYSTEM |
EXPERT OPINION ON DRUG SAFETY 23 (5): 617-625 MAY 3 2024 |
10.1080/14740338.2024.2338251 |
PHARMACOLOGY & TOXICOLOGY |
54 |
|
20 |
USING CLUSTERPROFILER TO CHARACTERIZE MULTIOMICS DATA |
NATURE PROTOCOLS 19 (11): - NOV 2024 |
10.1038/s41596-024-01020-z |
BIOLOGY & BIOCHEMISTRY |
45 |
|
21 |
SINGLE-CELL TRANSCRIPTOME ANALYSIS REVEALS THE ASSOCIATION BETWEEN HISTONE LACTYLATION AND CISPLATIN RESISTANCE IN BLADDER CANCER |
DRUG RESISTANCE UPDATES 73: - MAR 2024 |
10.1016/j.drup.2024.101059 |
PHARMACOLOGY & TOXICOLOGY |
32 |
|
22 |
GLOBAL BURDEN OF METABOLIC DISEASES, 1990-2021021 |
METABOLISM-CLINICAL AND EXPERIMENTAL 160: - NOV 2024 |
10.1016/j.metabol.2024.155999 |
BIOLOGY & BIOCHEMISTRY |
28 |
|
23 |
TISLELIZUMAB PLUS PLATINUM AND ETOPOSIDE VERSUS PLACEBO PLUS PLATINUM AND ETOPOSIDE AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SCLC (RATIONALE-312): A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PHASE 3 CLINICAL TRIAL |
JOURNAL OF THORACIC ONCOLOGY 19 (7): 1073-1085 JUL 2024 |
10.1016/j.jtho.2024.03.008 |
CLINICAL MEDICINE |
24 |
|
24 |
THE ROLE OF DIETARY MODIFICATION IN THE PREVENTION AND MANAGEMENT OF METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE: AN INTERNATIONAL MULTIDISCIPLINARY EXPERT CONSENSUS |
METABOLISM-CLINICAL AND EXPERIMENTAL 161: - DEC 2024 |
10.1016/j.metabol.2024.156028 |
BIOLOGY & BIOCHEMISTRY |
12 |
|
25 |
MULTI-OMICS IDENTIFICATION OF A SIGNATURE BASED ON MALIGNANT CELL-ASSOCIATED LIGAND-RECEPTOR GENES FOR LUNG ADENOCARCINOMA |
BMC CANCER 24 (1): - SEP 12 2024 |
10.1186/s12885-024-12911-5 |
CLINICAL MEDICINE |
11 |
|
26 |
VARIANTS IN EP400, ENCODING A CHROMATIN REMODELER, CAUSE EPILEPSY WITH NEURODEVELOPMENTAL DISORDERS |
AMERICAN JOURNAL OF HUMAN GENETICS 112 (1): - JAN 2 2025 |
10.1016/j.ajhg.2024.11.010 |
MOLECULAR BIOLOGY & GENETICS |
4 |
